Abiopharma

🔍 Borthwick Kathleen (Executive)

Company: Passage BIO, Inc. (PASG)

Report Date: 2026-01-08

Detailed Transactions and Holdings:

• Acquired 5,000 shares of Common Stock (Direct)
  Date: 2026-01-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 7,464.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 2,062 shares of Common Stock at $18.4394 per share (Direct)
  Date: 2026-01-08 | Code: S | equity_swap_involved: 0 | shares_owned_after: 5,402.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 5,000 shares of Restricted Stock Unit (Derivative)
  Date: 2026-01-08 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,000.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5

Footnotes:

• F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
• F2: Includes 200 shares acquired on May 15, 2025 and 200 shares acquired on November 15, 2025 under the 2020 Employee Stock Purchase Plan.
• F3: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
• F4: The reported price in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple security holders of the Issuer in multiple transactions at prices ranging from $18.13 to $19.3061 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 4 with regard to the block trade.
• F5: 50% of the total RSUs will vest on January 8, 2026 and the remaining 50% of the RSUs will vest on January 8, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.